Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL)

被引：2
作者：
Marciscano, Ariel E. [1 ]
Gupta, Neel [2 ]
Zhang, Zhigang [2 ]
Teruya-Feldstein, Julie [2 ]
Noy, Ariela [2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
10.1182/blood.V112.11.837.837
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：310 / 310
页数：1
相关论文
共 50 条
  • [41] Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.
    Hawkes, Eliza Anne
    Manos, Kate
    Chong, Geoffrey
    Palmer, Jodie
    MacManus, Michael Patrick
    Keane, Colm
    Scott, Andrew Mark
    Shortt, Jake
    Ritchie, David
    Churilov, Leonid
    Johnston, Laura
    Witkowski, Tom
    Barraclough, Allison Anne
    Lee, Sze Ting
    Lin, Wendi
    Koldej, Rachel
    Khor, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
    Ghielmini, M.
    Vitolo, U.
    Kimby, E.
    Montoto, S.
    Walewski, J.
    Pfreundschuh, M.
    Federico, M.
    Hoskin, P.
    McNamara, C.
    Caligaris-Cappio, F.
    Stilgenbauer, S.
    Marcus, R.
    Trneny, M.
    Dreger, P.
    Montserrat, E.
    Dreyling, M.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 561 - 576
  • [43] Prognostic markers and angiogenesis in diffuse large B-cell lymphoma and follicular lymphoma
    Mezei, T.
    Gurzu, S.
    Raica, M.
    Cimpean, A.
    Szentirmay, J.
    Jung, J.
    VIRCHOWS ARCHIV, 2009, 455 : 17 - 18
  • [44] A Patient With Regressed Diffuse Large B-Cell Lymphoma and Aggressive Follicular Lymphoma
    Sethi, Ashish K.
    Haq, Bushra
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (05)
  • [45] Primary prostatic lymphoma with components of both diffuse large B-cell lymphoma (DLBCL) and MALT lymphoma
    Petrakis, G.
    Koletsa, T.
    Karavasilis, V
    Rallis, G.
    Bobos, M.
    Karkavelas, G.
    Kostopoulos, I
    HIPPOKRATIA, 2012, 16 (01) : 86 - 89
  • [46] Prognostication of diffuse large B-cell lymphoma in the rituximab era
    Ninan, Mary J.
    Wadhwa, Punit D.
    Gupta, Pankaj
    LEUKEMIA & LYMPHOMA, 2011, 52 (03) : 360 - 373
  • [47] PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Rozman, S.
    Grabnar, I.
    Novakovic, S.
    Mrhar, A.
    Novakovic, B. Jezersek
    HAEMATOLOGICA, 2017, 102 : 688 - 688
  • [48] Rituximab maintenance therapy in diffuse large B-cell lymphoma
    Trajkova, S.
    Panovska-Stavridis, I.
    Stojanovik, A.
    Dukovski, D.
    Cevreska, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S23
  • [49] The role of CNS prophylaxis in diffuse large B-cell lymphoma (DLBCL)
    Korfel, A.
    ONKOLOGIE, 2010, 33 : 26 - 27
  • [50] Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL)
    Talaulikar, D.
    Dahlstrom, J.
    Shadbolt, B.
    Broomfield, A.
    McDonald, A.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2008, 30 : 146 - 147
12345